Stay updated on Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, v2.15.2, and the previous version, v2.15.0, has been removed. Additionally, a date of April 30, 2025, has been added.
    Difference
    1.0%
    Check dated 2025-04-30T20:22:20.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.15.0, replacing the previous version 2.14.4.
    Difference
    1.0%
    Check dated 2025-04-16T13:50:26.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 24, 2025.
    Difference
    0.6%
    Check dated 2025-04-09T08:45:13.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page has updated the reference to Seagen, now explicitly stating it as a wholly owned subsidiary of Pfizer, and has changed a date from March 12, 2025, to March 24, 2025.
    Difference
    3%
    Check dated 2025-03-25T13:57:23.000Z thumbnail image
  8. Check
    69 days ago
    Change Detected
    Summary
    The date '2025-03-12' has been added, while '2024-11-13' has been removed from the page.
    Difference
    1.0%
    Check dated 2025-03-18T08:54:16.000Z thumbnail image
  9. Check
    90 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    5%
    Check dated 2025-02-24T21:08:38.000Z thumbnail image

Stay in the know with updates to Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.